Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.
Hydrocortisone is not recommended for long-term use on the scalp due to potential side effects like thinning and steroid-related issues. Alternatives like foam minoxidil or oral minoxidil are suggested, though foam may be less effective.
A user shared progress pictures after nearly four months on finasteride, reporting halted shedding and improved hair density. They incorporated a scalp scrubber and Nizoral into their routine, with others sharing similar experiences and encouragement.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
A user is considering starting spironolactone for hair loss without consulting a dermatologist, as previous dermatologists only recommended biotin, vitamins, or PRP. The user notes that spironolactone is affordable in their country.
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
A user shared their experience with Finasteride for hair loss, noting improvement but still some thinning. They plan to get a hair transplant to address remaining thin spots and strengthen their hairline.
The conclusion of the conversation is that dying the hair can be an effective method for managing hair loss, particularly for those with diffuse thinning.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.